EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME

被引：0
|
作者：
Lee, Dae Wook [1 ]
Monteiro, Pedro [2 ]
Clark, Douglas [3 ]
Hantel, Stefan [3 ]
Woerle, Hans J. [3 ]
Inzucchi, Silvio E. [4 ]
Fitchett, David [5 ]
机构：
[1] Boehringer Ingelheim Korea, Med Affairs, Dept Med Affairs Metab, Seoul, South Korea
[2] Univ Coimbra, Dept Coimbra Hosp, Coimbra, Portugal
[3] Boehringer Ingelheim Pharma GmbH & Co KG, GmbH & Co KG, Ingelheim, Germany
[4] Yale Univ, Sch Med, Dept Endocrinol, New Haven, CT 06520 USA
[5] Univ Toronto, St Michaels Hosp, Dept Cardiol, Toronto, ON, Canada
来源：
JOURNAL OF HYPERTENSION | 2016年 / 34卷
关键词：
D O I：
10.1097/01.hjh.0000501423.64635.bd
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
LBPS 02-52
引用
收藏
页码：E520 / E520
页数：1
相关论文
共 50 条
  • [1] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [2] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [3] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. -J.
    Inzucchi, S. E.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S534
  • [4] Effect of empagliflozin on nephropathy in subgroups by age: results from EMPA-REG OUTCOME
    von Eynatten, M.
    Bergenstal, R. M.
    Calabro, P.
    Maldonado-Lutomirsky, M.
    Mattheus, M.
    Lachin, J. M.
    Wanner, C.
    DIABETOLOGIA, 2016, 59 : S483 - S483
  • [5] Effect of Empagliflozin on Nephropathy in Subgroups by Age: Results from EMPA-REG Outcome
    Bergenstal, Richard M.
    Calabro, Paolo
    Lutomirsky, Mario Maldonado
    Von Eynatten, Maximillian
    Mattheus, Michaela
    Wanner, John Lachin Christoph
    DIABETES, 2016, 65 : A314 - A314
  • [6] EFFECT OF EMPAGLIFLOZIN ON NEPHROPATHY IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    D'Emden, M.
    Bergenstal, R.
    Lutomirsky, Maldonado M.
    Wanner, C.
    NEPHROLOGY, 2016, 21 : 59 - 59
  • [7] Effect of Empagliflozin on Cardiovascular Death in Subgroups by Age: Results from EMPA-REG Outcome
    Ridderstrale, Martin
    Toural, Elvira
    Fitchett, David
    Kis, Sanja Giljanovic
    Woerle, Hans J.
    Mattheus, Michaela
    Zinman, Bernard
    Inzucchi, Silvio E.
    DIABETES, 2016, 65 : A289 - A290
  • [8] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1192 - 1192
  • [9] Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME
    Toural, E.
    Ridderstrale, M.
    Fitchett, D.
    Kis, S. Giljanovic
    Woerle, H. -J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S. E.
    DIABETOLOGIA, 2016, 59 : S539 - S540
  • [10] Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME
    Schnee, J.
    Inzucchi, S. E.
    Zinman, B.
    McGinniss, J.
    George, J. T.
    Fitchett, D.
    DIABETOLOGIA, 2017, 60 : S85 - S86
12345